{"id":"NCT02607618","sponsor":"Motif Bio","briefTitle":"Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2","officialTitle":"A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11","primaryCompletion":"2017-08-08","completion":"2017-08-08","firstPosted":"2015-11-18","resultsPosted":"2018-07-11","lastUpdate":"2018-08-07"},"enrollment":613,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Skin Structures and Soft Tissue Infections"],"interventions":[{"type":"DRUG","name":"Iclaprim","otherNames":["MTF-100"]},{"type":"DRUG","name":"Vancomycin","otherNames":["Vancocin"]}],"arms":[{"label":"iclaprim","type":"EXPERIMENTAL"},{"label":"vancomycin","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.","primaryOutcome":{"measure":"Percent of Participants With ≥20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline","timeFrame":"Baseline and 48 to 72 hours after first dose of study drug","effectByArm":[{"arm":"Iclaprim","deltaMin":78.3,"sd":null},{"arm":"Vancomycin","deltaMin":76.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":54,"countries":["United States","Argentina","Belgium","Croatia","Czechia","Estonia","Hungary","Portugal","Romania","Turkey (Türkiye)"]},"refs":{"pmids":["29783024","29530858"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":299},"commonTop":["Product Issues"]}}